Skip to main content
PMC home page
British Heart Journal logoLink to British Heart Journal
. 1991 Aug;66(2):119–121. doi: 10.1136/hrt.66.2.119

The treatment of primary pulmonary hypertension.

N G Uren, C M Oakley
PMCID: PMC1024600  PMID: 1883661

Full text

PDF
119

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. "Pulmonary pulseless disease:" pulmonary involvement in so-called Takayasu's disease. Clinical Conference in Cardiology from the third medical division, Kyoto University Hospital, Kyoto, Japan. Chest. 1978 May;73(5):651–657. [PubMed] [Google Scholar]
  2. Asherson R. A., Oakley C. M. Pulmonary hypertension and systemic lupus erythematosus. J Rheumatol. 1986 Feb;13(1):1–5. [PubMed] [Google Scholar]
  3. Bjornsson J., Edwards W. D. Primary pulmonary hypertension: a histopathologic study of 80 cases. Mayo Clin Proc. 1985 Jan;60(1):16–25. doi: 10.1016/s0025-6196(12)65277-x. [DOI] [PubMed] [Google Scholar]
  4. Bourdillon P. D., Oakley C. M. Regression of primary pulmonary hypertension. Br Heart J. 1976 Mar;38(3):264–270. doi: 10.1136/hrt.38.3.264. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Camerini F., Alberti E., Klugmann S., Salvi A. Primary pulmonary hypertension: effects of nifedipine. Br Heart J. 1980 Sep;44(3):352–356. doi: 10.1136/hrt.44.3.352. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Chang S. W., Voelkel N. F. Charge-related lung microvascular injury. Am Rev Respir Dis. 1989 Feb;139(2):534–545. doi: 10.1164/ajrccm/139.2.534. [DOI] [PubMed] [Google Scholar]
  7. DRESDALE D. T., MICHTOM R. J., SCHULTZ M. Recent studies in primary pulmonary hypertension, including pharmacodynamic observations on pulmonary vascular resistance. Bull N Y Acad Med. 1954 Mar;30(3):195–207. [PMC free article] [PubMed] [Google Scholar]
  8. Douglas J. S., Jr Hemodynamic effects of nifedipine in primary pulmonary hypertension. J Am Coll Cardiol. 1983 Jul;2(1):174–179. doi: 10.1016/s0735-1097(83)80389-1. [DOI] [PubMed] [Google Scholar]
  9. Eysmann S. B., Palevsky H. I., Reichek N., Hackney K., Douglas P. S. Two-dimensional and Doppler-echocardiographic and cardiac catheterization correlates of survival in primary pulmonary hypertension. Circulation. 1989 Aug;80(2):353–360. doi: 10.1161/01.cir.80.2.353. [DOI] [PubMed] [Google Scholar]
  10. Fujii A., Rabinovitch M., Matthews E. C. A case of spontaneous resolution of idiopathic pulmonary hypertension. Br Heart J. 1981 Nov;46(5):574–577. doi: 10.1136/hrt.46.5.574. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Fuster V., Steele P. M., Edwards W. D., Gersh B. J., McGoon M. D., Frye R. L. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation. 1984 Oct;70(4):580–587. doi: 10.1161/01.cir.70.4.580. [DOI] [PubMed] [Google Scholar]
  12. Glanville A. R., Burke C. M., Theodore J., Robin E. D. Primary pulmonary hypertension. Length of survival in patients referred for heart-lung transplantation. Chest. 1987 May;91(5):675–681. doi: 10.1378/chest.91.5.675. [DOI] [PubMed] [Google Scholar]
  13. Gurtner H. P. Aminorex and pulmonary hypertension. A review. Cor Vasa. 1985;27(2-3):160–171. [PubMed] [Google Scholar]
  14. Gómez-Sánchez M. A., Mestre de Juan M. J., Gómez-Pajuelo C., López J. I., Díaz de Atauri M. J., Martínez-Tello F. J. Pulmonary hypertension due to toxic oil syndrome. A clinicopathologic study. Chest. 1989 Feb;95(2):325–331. doi: 10.1378/chest.95.2.325. [DOI] [PubMed] [Google Scholar]
  15. HEATH D., EDWARDS J. E. The pathology of hypertensive pulmonary vascular disease; a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation. 1958 Oct;18(4 Pt 1):533–547. doi: 10.1161/01.cir.18.4.533. [DOI] [PubMed] [Google Scholar]
  16. Hales C. A., Kradin R. L., Brandstetter R. D., Zhu Y. J. Impairment of hypoxic pulmonary artery remodeling by heparin in mice. Am Rev Respir Dis. 1983 Oct;128(4):747–751. doi: 10.1164/arrd.1983.128.4.747. [DOI] [PubMed] [Google Scholar]
  17. Heath D., Smith P., Gosney J., Mulcahy D., Fox K., Yacoub M., Harris P. The pathology of the early and late stages of primary pulmonary hypertension. Br Heart J. 1987 Sep;58(3):204–213. doi: 10.1136/hrt.58.3.204. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Hislop A., Reid L. Arterial changes in Crotalaria spectabilis-induced pulmonary hypertension in rats. Br J Exp Pathol. 1974 Apr;55(2):153–163. [PMC free article] [PubMed] [Google Scholar]
  19. Hughes J. D., Rubin L. J. Primary pulmonary hypertension. An analysis of 28 cases and a review of the literature. Medicine (Baltimore) 1986 Jan;65(1):56–72. [PubMed] [Google Scholar]
  20. Jones D. K., Higenbottam T. W., Wallwork J. Treatment of primary pulmonary hypertension intravenous epoprostenol (prostacyclin). Br Heart J. 1987 Mar;57(3):270–278. doi: 10.1136/hrt.57.3.270. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Kambara H., Fujimoto K., Wakabayashi A., Kawai C. Primary pulmonary hypertension: beneficial therapy with diltiazem. Am Heart J. 1981 Feb;101(2):230–231. doi: 10.1016/0002-8703(81)90672-4. [DOI] [PubMed] [Google Scholar]
  22. Kanemoto N., Sasamoto H. Pulmonary hemodynamics in primary pulmonary hypertension. Jpn Heart J. 1979 Jul;20(4):395–405. doi: 10.1536/ihj.20.395. [DOI] [PubMed] [Google Scholar]
  23. Landmark K., Refsum A. M., Simonsen S., Storstein O. Verapamil and pulmonary hypertension. Acta Med Scand. 1978;204(4):299–302. doi: 10.1111/j.0954-6820.1978.tb08443.x. [DOI] [PubMed] [Google Scholar]
  24. Loyd J. E., Atkinson J. B., Pietra G. G., Virmani R., Newman J. H. Heterogeneity of pathologic lesions in familial primary pulmonary hypertension. Am Rev Respir Dis. 1988 Oct;138(4):952–957. doi: 10.1164/ajrccm/138.4.952. [DOI] [PubMed] [Google Scholar]
  25. McCarthy P. M., Starnes V. A., Theodore J., Stinson E. B., Oyer P. E., Shumway N. E. Improved survival after heart-lung transplantation. J Thorac Cardiovasc Surg. 1990 Jan;99(1):54–60. [PubMed] [Google Scholar]
  26. McGoon M. D., Vlietstra R. E. Vasodilator therapy for primary pulmonary hypertension. Mayo Clin Proc. 1984 Oct;59(10):672–677. doi: 10.1016/s0025-6196(12)62055-2. [DOI] [PubMed] [Google Scholar]
  27. Morrison E. B., Gaffney F. A., Eigenbrodt E. H., Reynolds R. C., Buja L. M. Severe pulmonary hypertension associated with macronodular (postnecrotic) cirrhosis and autoimmune phenomena. Am J Med. 1980 Oct;69(4):513–519. doi: 10.1016/0002-9343(80)90461-1. [DOI] [PubMed] [Google Scholar]
  28. Mustard J. F., Packham M. A. Thromboembolism: a manifestation of the response of blood to injury. Circulation. 1970 Jul;42(1):1–21. doi: 10.1161/01.cir.42.1.1. [DOI] [PubMed] [Google Scholar]
  29. Newman J. H., Ross J. C. Primary pulmonary hypertension: a look at the future. J Am Coll Cardiol. 1989 Sep;14(3):551–555. doi: 10.1016/0735-1097(89)90091-0. [DOI] [PubMed] [Google Scholar]
  30. Oakley C. M. Management of primary pulmonary hypertension. Br Heart J. 1985 Jan;53(1):1–4. doi: 10.1136/hrt.53.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Packer M., Greenberg B., Massie B., Dash H. Deleterious effects of hydralazine in patients with pulmonary hypertension. N Engl J Med. 1982 Jun 3;306(22):1326–1331. doi: 10.1056/NEJM198206033062203. [DOI] [PubMed] [Google Scholar]
  32. Packer M. Is it ethical to administer vasodilator drugs to patients with primary pulmonary hypertension? Chest. 1989 Jun;95(6):1173–1175. doi: 10.1378/chest.95.6.1173. [DOI] [PubMed] [Google Scholar]
  33. Packer M. Vasodilator therapy for primary pulmonary hypertension. Limitations and hazards. Ann Intern Med. 1985 Aug;103(2):258–270. doi: 10.7326/0003-4819-103-2-258. [DOI] [PubMed] [Google Scholar]
  34. Palevsky H. I., Schloo B. L., Pietra G. G., Weber K. T., Janicki J. S., Rubin E., Fishman A. P. Primary pulmonary hypertension. Vascular structure, morphometry, and responsiveness to vasodilator agents. Circulation. 1989 Nov;80(5):1207–1221. doi: 10.1161/01.cir.80.5.1207. [DOI] [PubMed] [Google Scholar]
  35. Reeves J. T., Groves B. M., Turkevich D. The case for treatment of selected patients with primary pulmonary hypertension. Am Rev Respir Dis. 1986 Aug;134(2):342–346. doi: 10.1164/arrd.1986.134.2.342. [DOI] [PubMed] [Google Scholar]
  36. Rich S., Brundage B. H. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation. 1987 Jul;76(1):135–141. doi: 10.1161/01.cir.76.1.135. [DOI] [PubMed] [Google Scholar]
  37. Rich S., Brundage B. H., Levy P. S. The effect of vasodilator therapy on the clinical outcome of patients with primary pulmonary hypertension. Circulation. 1985 Jun;71(6):1191–1196. doi: 10.1161/01.cir.71.6.1191. [DOI] [PubMed] [Google Scholar]
  38. Rich S., Brundage B. H. Pulmonary hypertension: a cellular basis for understanding the pathophysiology and treatment. J Am Coll Cardiol. 1989 Sep;14(3):545–550. doi: 10.1016/0735-1097(89)90090-9. [DOI] [PubMed] [Google Scholar]
  39. Rich S., Ganz R., Levy P. S. Comparative actions of hydralazine, nifedipine and amrinone in primary pulmonary hypertension. Am J Cardiol. 1983 Nov 1;52(8):1104–1107. doi: 10.1016/0002-9149(83)90541-6. [DOI] [PubMed] [Google Scholar]
  40. Rich S., Kieras K., Hart K., Groves B. M., Stobo J. D., Brundage B. H. Antinuclear antibodies in primary pulmonary hypertension. J Am Coll Cardiol. 1986 Dec;8(6):1307–1311. doi: 10.1016/s0735-1097(86)80301-1. [DOI] [PubMed] [Google Scholar]
  41. Rich S., Levy P. S. Characteristics of surviving and nonsurviving patients with primary pulmonary hypertension. Am J Med. 1984 Apr;76(4):573–578. doi: 10.1016/0002-9343(84)90279-1. [DOI] [PubMed] [Google Scholar]
  42. Rich S. Primary pulmonary hypertension. Prog Cardiovasc Dis. 1988 Nov-Dec;31(3):205–238. doi: 10.1016/0033-0620(88)90016-3. [DOI] [PubMed] [Google Scholar]
  43. Rozkovec A., Montanes P., Oakley C. M. Factors that influence the outcome of primary pulmonary hypertension. Br Heart J. 1986 May;55(5):449–458. doi: 10.1136/hrt.55.5.449. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Rozkovec A., Stradling J. R., Shepherd G., MacDermot J., Oakley C. M., Dollery C. T. Prediction of favourable responses to long term vasodilator treatment of pulmonary hypertension by short term administration of epoprostenol (prostacyclin) or nifedipine. Br Heart J. 1988 Jun;59(6):696–705. doi: 10.1136/hrt.59.6.696. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Rubin L. J., Groves B. M., Reeves J. T., Frosolono M., Handel F., Cato A. E. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation. 1982 Aug;66(2):334–338. doi: 10.1161/01.cir.66.2.334. [DOI] [PubMed] [Google Scholar]
  46. Rubin L. J., Peter R. H. Oral hydralazine therapy for primary pulmonary hypertension. N Engl J Med. 1980 Jan 10;302(2):69–73. doi: 10.1056/NEJM198001103020201. [DOI] [PubMed] [Google Scholar]
  47. Ruoslahti E., Pierschbacher M. D. New perspectives in cell adhesion: RGD and integrins. Science. 1987 Oct 23;238(4826):491–497. doi: 10.1126/science.2821619. [DOI] [PubMed] [Google Scholar]
  48. Salerni R., Rodnan G. P., Leon D. F., Shaver J. A. Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma). Ann Intern Med. 1977 Apr;86(4):394–399. doi: 10.7326/0003-4819-86-4-394. [DOI] [PubMed] [Google Scholar]
  49. Sanderson J. E., Spiro S. G., Hendry A. T., Turner-Warwick M. A case of pulmonary veno-occlusive disease respondong to treatment with azathioprine. Thorax. 1977 Apr;32(2):140–148. doi: 10.1136/thx.32.2.140. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Stumpe K. O., Schmengler K., Bette L., Overlack A., Kolloch R. Persistent hemodynamic and clinical improvement after captopril in patients with pulmonary hypertension. Herz. 1986 Aug;11(4):217–225. [PubMed] [Google Scholar]
  51. Sullivan W. D., Hurst D. J., Harmon C. E., Esther J. H., Agia G. A., Maltby J. D., Lillard S. B., Held C. N., Wolfe J. F., Sunderrajan E. V. A prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease. Medicine (Baltimore) 1984 Mar;63(2):92–107. doi: 10.1097/00005792-198403000-00003. [DOI] [PubMed] [Google Scholar]
  52. Thadani U., Burrow C., Whitaker W., Heath D. Pulmonary veno-occlusive disease. Q J Med. 1975 Jan;44(173):133–159. [PubMed] [Google Scholar]
  53. Tobin M. J., Yang K., Upson D. Breathing pattern in asthma. Chest. 1989 Jan;95(1):1–2. doi: 10.1378/chest.95.1.1. [DOI] [PubMed] [Google Scholar]
  54. Vanhoutte P. M., Shimokawa H. Endothelium-derived relaxing factor and coronary vasospasm. Circulation. 1989 Jul;80(1):1–9. doi: 10.1161/01.cir.80.1.1. [DOI] [PubMed] [Google Scholar]
  55. WIDIMSKY J., KASALICKY J., DEJDAR R., VYSLOUZIL Z., LUKES M. Effect of reserpine on the lesser circulation in chronic pulmonary diseases. Br Heart J. 1962 May;24:274–278. doi: 10.1136/hrt.24.3.274. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. WOOD P. Pulmonary hypertension with special reference to the vasoconstrictive factor. Br Heart J. 1958 Oct;20(4):557–570. doi: 10.1136/hrt.20.4.557. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. WOOD P. Pulmonary hypertension. Br Med Bull. 1952;8(4):348–353. doi: 10.1093/oxfordjournals.bmb.a074201. [DOI] [PubMed] [Google Scholar]
  58. Wakaki K., Koizumi F., Fukase M. Vascular lesions in systemic lupus erythematosus (SLE) with pulmonary hypertension. Acta Pathol Jpn. 1984 May;34(3):593–604. doi: 10.1111/j.1440-1827.1984.tb07587.x. [DOI] [PubMed] [Google Scholar]
  59. Watkins W. D., Peterson M. B., Crone R. K., Shannon D. C., Levine L. Prostacyclin and prostaglandin E1 for severe idiopathic pulmonary artery hypertension. Lancet. 1980 May 17;1(8177):1083–1083. doi: 10.1016/s0140-6736(80)91522-6. [DOI] [PubMed] [Google Scholar]
  60. Young R. H., Mark G. J. Pulmonary vascular changes in scleroderma. Am J Med. 1978 Jun;64(6):998–1004. doi: 10.1016/0002-9343(78)90455-2. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES